EVALUATION OF THE IMPACT OF METABOLIC SYNDROME ON THE COURSE AND PROGNOSIS OF PROSTATE CANCER

Аннотация

Prostate cancer (PCa) remains one of the most commonly diagnosed cancers in men worldwide, and its prognosis is influenced by various factors including genetic, environmental, and lifestyle-related determinants. Metabolic syndrome (MetS) is a cluster of metabolic abnormalities including central obesity, hyperglycemia, hypertension, and dyslipidemia, which are increasingly prevalent and thought to play a role in the development and progression of various cancers. This study aims to evaluate the impact of metabolic syndrome on the course and prognosis of prostate cancer. We conducted a retrospective analysis of 200 prostate cancer patients, assessing their metabolic profile and correlating it with clinical outcomes such as tumor stage, progression-free survival, and overall survival. Our findings suggest that metabolic syndrome significantly correlates with advanced stage disease, higher Gleason scores, and shorter progression-free survival. The study underscores the importance of addressing metabolic risk factors in prostate cancer management and highlights the need for integrated treatment approaches that address both oncological and metabolic health. Keywords: Prostate cancer, metabolic syndrome, prognosis, progression-free survival, Gleason score, hypertension, dyslipidemia, obesity, hyperglycemia, clinical outcomes Introduction: Prostate cancer (PCa) is one of the leading causes of cancer-related mortality in men. While early detection and advancements in treatment have improved survival rates, the progression and prognosis of prostate cancer still vary significantly between patients. A range of factors, including genetic predisposition, lifestyle, and comorbidities, play a crucial role in influencing disease outcomes. One such comorbidity is metabolic syndrome (MetS), a cluster of metabolic disorders that include abdominal obesity, hypertension, dyslipidemia, and insulin resistance. Metabolic syndrome is often associated with increased risk for cardiovascular diseases and type 2 diabetes, but its impact on cancer progression, particularly prostate cancer, has garnered increasing attention. Recent studies have indicated that metabolic syndrome could potentially influence prostate cancer progression through various biological mechanisms, such as increased levels of inflammatory cytokines, alterations in insulin signaling, and the promotion of angiogenesis. These factors may not only contribute to the development of prostate cancer but may also worsen its prognosis. This study aims to investigate the role of metabolic syndrome in prostate cancer progression by correlating metabolic risk factors with clinical outcomes in prostate cancer patients.